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ABSTRACT
Ample evidence supports that prostate tumor metastasis originates from a 
rare population of cancer cells, known as cancer stem cells (CSCs). Unfortunately, 
little is known about the identity of these cells, making it difficult to target the 
metastatic prostate tumor. Here, for the first time, we report the identification of a 
rare population of prostate cancer cells that express the Tie-2 protein. We found that 
this Tie-2High population exists mainly in prostate cancer cell lines that are capable of 
metastasizing to the bone. These cells not only express a higher level of CSC markers 
but also demonstrate enhanced resistance to the chemotherapeutic drug Cabazitaxel. 
In addition, knockdown of the expression of the Tie-2 ligand angiopoietin (Ang-
1) led to suppression of CSC markers, suggesting that the Ang-1/Tie-2 signaling 
pathway functions as an autocrine loop for the maintenance of prostate CSCs. More 
importantly, we found that Tie-2High prostate cancer cells are more adhesive than the 
Tie-2Low population to both osteoblasts and endothelial cells. Moreover, only the Tie-
2High, but not the Tie-2Low cells developed tumor metastasis in vivo when injected at a 
low number. Taken together, our data suggest that Tie-2 may play an important role 
during the development of prostate tumor metastasis.
INTRODUCTION
Prostate cancer is one of the most common 
solid tumors in men and is the second leading cause of 
morbidity and mortality in men worldwide [1, 2]. Patients 
with advanced prostate cancer are normally treated with 
hormone ablation therapy. This therapy is effective 
initially, as prostate cancer cells require androgen to grow 
and survive; however, the cancer cells eventually become 
androgen-independent and develop metastatic, castration-
resistant tumors [3]. At this stage, chemotherapy and 
radiotherapy have only minor benefits. As a result, 
advanced prostate cancer remains incurable with current 
treatment strategies [4].
Recent studies suggested that prostate tumor-
initiating cells (TICs)/cancer stem cells (CSCs) may 
play key roles in the initiation, progression and treatment 
failure of the disease [5-7]; however, their exact identity 
remains unclear. These cells share many similarities with 
normal stem cells, including the ability to differentiate 
into cells of different lineages and the dependence on a 
stem cell niche for the maintenance of their stemness. 
Interestingly, according to previous studies, CSCs are 
capable of creating their own CSC niche by recruiting 
mesenchymal stem cells derived from bone marrow [8]. 
CSCs can also ‘hijack’ the established normal stem cell 
niches [9]; as has been demonstrated in both human and 
mouse models of prostate and breast cancers. According 
to Shiozawa et al. [10], prostate CSCs are capable of 
competing with hematopoietic stem cells (HSCs) for 
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the bone marrow niche. Moreover, prostate cancer cells 
that occupy the niche were found to express the CXCR4 
receptor, which is responsible for mediating the interaction 
between HSCs and the niche. By blocking the CXCL12/
CXCR4 pathway, prostate cancer bone metastasis was 
significantly suppressed, supporting the hypothesis that 
prostate tumors metastasize to the bone by adopting this 
bone-homing signaling pathway. However, although 
disseminated prostate cancer cells can be detected in the 
bone marrow of prostate cancer patients, bone metastasis 
may take years to develop. This may reflect the time 
required for the disseminated cancer cells to establish 
a suitable tumor microenvironment before the cells can 
grow exponentially. Therefore, a better understanding of 
the bone marrow stem cell niche and its role in supporting 
bone metastasis may aid the development of effective 
treatments.
Tie-2 is a membrane receptor commonly expressed 
by HSCs, osteoblasts and endothelial cells. It binds to and 
is activated by angiopoietin-1 (Ang-1), a cytokine actively 
secreted by osteoblasts within the bone marrow niche [11-
13]. Similar to the KITLG/c-Kit, CXCL12/CXCR4 and 
FGF1/FGFR chemokine axes, the Ang-1/Tie-2 signalling 
pathway also plays a key role in regulating the homing and 
stemness of HSCs [14-18]. According to Arai et al. [15], 
Tie-2 receptors are expressed by the quiescent HSCs that 
adhere to osteoblasts within the inner surface of the bone. 
The same group further demonstrated that osteoblasts 
secrete a large amount of Ang-1, which promotes the 
adhesion of HSCs to osteoblasts while maintaining 
the cells in a quiescent state. Recently, the Ang-1/Tie-2 
signalling pathway was also found to promote muscle 
satellite cell self-renewal [19]. Apart from regulating 
normal stem cells, Tie-2 was also found to play a role in 
cancer progression. As reported by Lee et al. [20], Tie-2 
was found to be expressed by neoplastic glial cells, and its 
expression level was significantly associated with disease 
progression. Tie-2 activation was also found to correlate 
with chemoresistance [21]. Further research by the same 
group demonstrated that Tie-2 promoted glioma cell 
invasion and modulated the interaction of glioma tumor 
stem cells with endothelial cells [22].
In this study, we show that Tie-2 is expressed 
by a rare population of prostate cancer cells that co-
express several CSC markers. Compared to the Tie-2Low 
population, Tie-2High prostate cancer cells demonstrate 
not only enhanced chemoresistance but also an increased 
ability to adhere to stromal cells such as endothelial cells 
and osteoblasts. Intra-cardiac injection of the cells into 
immune-incompetent mice confirmed that Tie-2High cells, 
but not Tie-2Low cells, actively developed into metastatic 
tumors in vivo. Our data, therefore, have demonstrated a 
novel role for Tie-2 in the development of prostate tumor 
metastasis.
RESULTS
Identification of a rare population of Tie-2High 
prostate cancer cells
Although Ang-1/Tie-2 is one of the key signalling 
pathways involved in HSC maintenance, it is currently 
unknown whether it plays any role in prostate cancer 
progression. To address this question, we first examined 
whether prostate cancer cells express Tie-2. Using a 
PE-conjugated anti Tie-2 antibody, the expression level 
of the Tie-2 receptor in a panel of prostate cancer cell 
lines with different metastatic potential (LAPC4, 22Rv1, 
DU145, LNCaP, C42B, MDA-PCa-2b and PC-3) was 
determined by flow cytometry. As shown in Figure 1A and 
1B, Tie-2 positive cells exist at a very low level in soft 
tissue metastatic prostate cancer cell lines (between 0.1 - 
0.15%). However, the Tie-2 positive population was found 
higher in C42B (a bone metastatic cell line derived from 
LNCaP) (0.35%), and two bone metastatic prostate cancer 
cell lines (0.33% and 0.39% in PC-3 and MDA-PCa-2b 
respectively). Consistently, qRT-PCR analysis revealed 
that Tie-2 mRNA was expressed at a higher level in the 
highly metastatic prostate cancer cell lines (Figure 1C). 
More importantly, Tie-2 was also found to be expressed 
not only in PC-3 tumors metastasized into a humanized 
bone scaffold (left panel) established in our previous study 
[23], but also in bone metastatic tumor of human prostate 
cancer patient (right panel), further suggesting that Tie-2 
may play roles in the development of prostate tumor bone 
metastasis (Figure 1D). 
Co-expression of stem cell markers with Tie-2 in 
prostate cancer cells
To further characterize the Tie-2 positive prostate 
cancer cells, we first performed FACS to enrich the 
Tie-2-positive population from PC-3 cells. Analysis of 
the population sorted by flow cytometry confirmed the 
successful enrichment of Tie-2High cells (Figure 2A) by cell 
sorting. cDNA microarray analysis was then performed 
to examine the gene expression profile of Tie-2High cells. 
As shown in in Suppl Table 2, several stem cell factors/
markers commonly found in HSCs (e.g. FGF1, KITLG 
and CXCR4) were found to be upregulated in the Tie-2High 
population, which was further confirmed by qRT-PCR 
analysis (Figure 2B), demonstrating that Tie-2 expression 
is associated with upregulation of HSC markers.
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Tie-2 regulates the quiescence of prostate cancer 
cells
One of the key roles of Tie-2 is to regulate the 
quiescence state of HSCs. To determine if expression of 
Tie-2 is associated with cellular quiescent, HO/PY staining 
was performed to quantitate quiescent population in both 
Tie-2High and Tie-2Low prostate cancer cells. As expected, 
the population of quiescent cells was increased more 
than 3-fold in the Tie-2High population when compared to 
the Tie-2Low population (Figure 2C), suggesting that Tie-
2 expression plays an important role in maintaining the 
quiescent state of prostate cancer cells. Cellular quiescence 
has been shown to contribute to the chemodrug resistance 
of CSCs. We therefore examined the sensitivity Tie-2High 
prostate cancer cells to Cabazitaxel, a chemotherapeutic 
drug commonly used for the treatment of prostate 
cancer. As shown in Figure 2D, treatment of the Tie-2Low 
population with Cabazitaxel led to induction of apoptosis 
of 48% cells, as evidenced by Annexin V staining. 
However, the apoptotic population was significantly 
lower in Tie-2High cells under the same conditions (<35%), 
clearly demonstrating that Tie-2 expression is associated 
with Cabazitaxel resistance.
Ang-1 activates the Tie-2 downstream signalling 
pathway in prostate cancer cells
Because the Ang-1/Tie-2 signalling cascade plays 
a role in the regulation of HSC stemness, we therefore 
questioned whether Ang-1 also regulates the stemness 
of prostate cancer cells. We first treated PC-3 cells with 
increasing doses of recombinant Ang-1 (0, 200 and 600 
ng/ml) for 72 hours under serum-free conditions. The 
expression of a series of stem cell factors/markers known 
to be induced by the Ang-1/Tie-2 signalling in HSCs was 
Figure 1: Expression of Tie-2 in prostate cancer cells. A.&B. Flow cytometry analysis of Tie-2 expression in a panel of prostate 
cancer cell lines (LAPC4, 22Rv1, DU145, LNCaP, C42B, MDA-PCa-2b and PC-3). The results are presented as the mean ± SD from 
triplicate experiments. C. Tie-2 mRNA was analyzed in these different prostate cancer cell lines using qRT-PCR. Note that Tie-2 protein 
and mRNA expression were both increased in bone metastatic prostate cancer cell lines (highlighted). Results quantified represented as 
fold change normalized to DU145. D. Immunohistochemical staining was performed on humanized bone scaffold containing the PC-3 
metastastic tumor (5 cases) (left panel) and human bone section containing the metastatic prostate tumor (1 case) (right panel). All the 
sections were stained with antibody against Tie-2. Note that, all the sections were positive for the Tie-2 proteins and the arrows showed the 
positive staining within the tumor cells (40X magnifications). 
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then examined by Western blotting. As shown in Figure 
3A (left panel), Ang-1 induced a dose-dependent increase 
in AKT phosphorylation, a direct downstream target 
of the Ang-1/Tie-2 signalling pathway, confirming that 
Tie-2 activates prostate cancer cells. More importantly, 
Ang-1 treatment was found to induce the expression of 
prostate CSC (CD49f and Bmi-1) and quiescence (p27) 
markers in PC-3 cells in a dose-dependent manner. When 
the cells were treated with a Tie-2 kinase inhibitor (0, 1 
and 5 µM), a cell permeabile pyridinylimidazole found 
to block the kinase activity of Tie-2 [24], all the markers 
tested were found to be downregulated, suggesting that 
activation of Tie-2 is required for maintaining the levels 
of these markers (Figure 3A, right panel). To confirm 
our findings, cells were transfected with two different 
siRNAs that target different regions of the Tie-2 mRNA, 
which resulted in a significant decrease (>50%) in the 
Tie-2 mRNA level (Figure 3B). As shown in Figure 3C, 
knockdown of Tie-2 led to concomitant decrease in the 
level of CD49f, Bmi-1 as well as p27. More interestingly, 
the effect of recombinant Ang-1 was significantly 
suppressed when the cells were pre-treated with the Tie-
2 inhibitor (Figure 3D, left panel) or Tie-2 Fc Chimera 
(Tie-2 neutralizing peptide) (Figure 3D, right panel). 
Furthermore, ectopic expression of Tie-2 in DU145 cells, 
which lack endogenous Tie-2 expression (Suppl Figure 
1A) and fail to respond to Ang-1 (data not shown), was 
found to successfully restore the response of the cells to 
Ang-1 treatment (Suppl Figure 1B), further supporting the 
hypothesis that activation of Tie-2 by Ang-1 is crucial for 
maintaining the expression of stem cell markers in prostate 
cancer cells. 
Since Ang-1 regulates the stemness of HSCs 
through induction of cellular quiescence, we therefore 
examined if Ang-1 treatment also induces quiescent of 
the prostate cancer cells. PC-3 cells were first treated with 
Ang-1 before being stained with HO/PY for quantitation 
of quiescent population. As shown in Figure 3E &3F, 
when cells were treated with recombinant Ang-1, a 
4-fold increase in the quiescent population was observed. 
Figure 2: The Tie-2High population possessed stem cell characteristics. A. Analysis of the population sorted by flow cytometry 
confirmed the successful enrichment of Tie-2High cells. B. Validation of the selected candidate genes (i.e., KITLG, CXCR4, and FGF1) 
with qRT-PCR. Results were normalized with internal control and are presented as fold change relative to Tie-2Low population. C. Flow 
cytometry analysis revealed that quiescent cells were increased by more than 3-fold in the Tie-2High population when compared to the Tie-
2Lowpopulation. D. Flow cytometry analysis of apoptotic cells by Annexin V staining in Tie-2Low and Tie-2High cells that were treated with 
100nM Cabazitaxel for 72hrs (p value = 0.0018 for apoptosis). Note that a high percentage of apoptotic cells were detected in the Tie-2Low 
population when compared to the Tie-2High prostate cancer cells. (p values: * < 0.05, ** < 0.005, *** < 0.0005). 
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Consistently, expression of p27, a protein closely 
associated with cell cycle arrest and cellular quiescence, 
was also found to be induced by Ang-1 treatment in PC-3 
cells (Figure 3A). Meanwhile, inactivation of Tie-2 using 
siRNA (Figure 3C), a Tie-2-specific inhibitor or a Tie-2 Fc 
chimera (Figure 3D) also led to suppression of p27, even 
in the presence of recombinant Ang-1, further suggesting 
that Ang-1 induces quiescence of prostate cancer cells 
through the activation of Tie-2. 
Ang-1 functions as a novel autocrine factor in 
prostate cancer cells
Because prostate cancer cells are known to secrete 
Ang-1, we hypothesized that Ang-1 may indeed function 
as an autocrine factor in prostate cancer cells. To test this 
hypothesis, we first confirmed the expression of Ang-1 
mRNA in the prostate cancer cell lines with qRT-PCR. 
Consistent with previous studies, Ang-1 mRNA was 
detectable in prostate cancer cell lines, and its expression 
is found higher in metastatic prostate cancer cell lines 
(Figure 4A). Nevertheless, transfection of PC-3 cells with 
two different Ang-1 siRNAs led to >80% suppression 
of the Ang-1 mRNA level, as shown in Figure 4B. 
More importantly, knockdown of endogenous Ang-1 
resulted in suppression of both CSC (CD49f an Bmi-
1) and quiescence (p27) markers in PC-3, supporting 
the hypothesis that Ang-1 produced by cancer cells is 
crucial for CSC maintenance (Figure 4C). Surprisingly, 
examination of Ang-1 secretion with ELISA revealed that 
C42B produced the highest level of Ang-1 among all the 
prostate cancer cell lines (Figure 4D). Meanwhile, we 
Figure 3: Ang-1 upregulated prostate CSC and quiescent markers in prostate cancer cell lines. Western blotting A. of 
prostate CSC markers (CD49f and Bmi-1) and a quiescence marker (p27) after Ang-1 treatment in PC-3 cells (left panel). Ang-1 was 
found to upregulate both stem cell and quiescence markers in a dose-dependent manner. The Tie-2 inhibitor, on the other hand, suppressed 
both types of markers in a dose-dependent manner in PC-3 cells (right panel). B. Transfection of Tie-2 siRNAs led to downregulation 
Tie-2 mRNA levels in PC-3 cells. Results were normalized with internal control and are presented as fold change relative to scramble. C. 
Effect of Tie-2 knockdown on CSC and quiescence marker expression in PC-3 cells. D. The experiment was repeated in the presence of 
Tie-2 inhibitor (left panel) or a Tie-2 neutralizing antibody (right panel), which showed that both the Tie-2 inhibitor and Tie-2 neutralizing 
antibody abolished the effect of Ang-1 on PC-3 cells. E. Quantitation of the quiescent population in PC-3 cells with or without Ang-1 
treatment. Note that Ang-1 treatment led to a 4-fold induction of the quiescent population in PC-3 cells when compared to the vehicle 
control. Each experiment was repeated at least three times, and the results are presented as the mean ± SD. (p values: * < 0.05, ** < 0.005, 
*** < 0.0005).
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found that C42B cells failed to respond to treatment with 
Ang-1 recombinant proteins (data not shown); however, 
knockdown of endogenous Ang-1 not only suppressed 
the expression of CD49f an Bmi-1, but also restored 
the response of the cells to exogenous Ang-1 treatment, 
as evidenced by the induction of CSC and quiescence 
markers by recombinant Ang-1 (Figure 4E-4G). These 
findings further confirm that Ang-1 regulates the stemness 
of prostate cancer cells by functioning as an autocrine 
factor.
Tie-2 facilitates the adhesion of prostate cancer 
cells to osteoblasts and endothelial cells
One of the functions of Tie-2 in HSC maintenance 
is to facilitate the adhesion of HSCs to osteoblasts, which 
is a process that is also required by prostate cancer cells 
during the development of bone metastasis. This led us 
to speculate that Tie-2 may also regulate the adhesion 
of prostate cancer cells to osteoblasts. The ability of 
the Tie-2High population to adhere to osteoblasts was 
then determined with a cell adhesion assay using the 
osteosarcoma cell line (MG-63). Examination of the cells 
that adhered to a confluent monolayer of MG-63 cells 
revealed a significant increase in the adhesion ability of 
the Tie-2High population to osteoblasts when compared 
to the Tie-2Low cells (Figure 5A). This adhesion ability 
was completely abolished in the presence of the Tie-2 
inhibitor, although the same treatment failed to affect the 
adhesion ability of the Tie-2Lowpopulation (Figure 5B). 
A similar result was observed in another osteosarcoma 
cell line (SaOS-2) (Suppl Figure 2A & 2B). Strikingly, 
we found that the Tie-2High population also showed an 
increased ability to adhere to endothelial cells (Figure 
5D), which again could be abolished by the addition of 
the Tie-2 inhibitor (Figure 5E). To determine whether this 
Figure 4: Ang-1 functioned as an autocrine factor in prostate cancer cells. A. Ang-1 mRNA expression was determined in 
different prostate cancer cell lines (DU145, C42B and PC-3) using qRT-PCR analysis. Results were normalized with internal control and 
are presented as fold change relative to DU145. B. Knockdown of Ang-1 in PC-3 cells by siRNA transfection was confirmed with qRT-
PCR and ELISA. Note that Ang-1 expression was suppressed by >80% in PC-3 cells. Results were normalized with internal control and are 
presented as fold change relative to scramble. C. Downregulation of Ang-1 in PC-3 cells by siRNA was associated with suppression of CSC 
(CD49f and Bmi-1) and quiescence (p27) markers. D. Ang-1 secretion (pg/ml) by different prostate cancer cell lines (DU145, C42B and 
PC-3) was determined with an ELISA. E. Knockdown of Ang-1 for >50% was confirmed with RT-PCR in C42B cells. F. Ang-1 knockdown 
suppressed both CSC (CD49f and Bmi-1) and quiescence (p27) markers in C42B cells. G. The response of C42B cells to exogenous Ang-1 
treatment (600ng/ml) was restored when endogenous Ang-1 was knocked down by siRNA. (p values: * < 0.05, ** < 0.005, *** < 0.0005).
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effect of Tie-2 is specific to PC-3 cells, we repeated the 
cell adhesion assay with DU-Tie-2-GFP. Similar to Tie-
2High PC-3 cells, DU-Tie-2-GFP cells also demonstrated 
increased adhesion to both MG-63 and HUVECs when 
compared to the control cells (DU-GFP), as shown in 
Figure 5C & 5F. Meanwhile, the adhesion ability of DU-
Tie-2-GFP cells to MG-63 and HUVECs was also able 
to abolish by the addition of Tie-2 inhibitor as shown 
in Suppl Figure 2C & 2D. Recently, Ang-1 has been 
shown to promote the bridging of intercellular Tie-2 
[25]. Considering that osteoblasts express high levels of 
Tie-2, it is possible that the cell adhesive ability of the 
Tie-2 positive prostate cancer cells is mediated through 
bridging of the intercellular Tie-2. Nevertheless, these 
findings provide strong evidence that Tie-2 promotes the 
adhesion of prostate cancer cells to both endothelial cells 
and osteoblasts.
Tie-2 enriched cells are highly metastatic in vivo
Because we found that higher levels of Tie-2 were 
expressed in metastatic prostate cancer cell lines, and 
conferred the preferential ability to induce a stem cell-like 
phenotype and cell adhesion ability of the cancer cells, 
we hypothesized that Tie-2 may play an important role 
in prostate tumor metastasis. To test this hypothesis, we 
examined the ability of Tie-2High prostate cancer cells to 
form metastatic tumors in vivo. Three thousand Tie-2High 
and Tie-2Low cells isolated from the PC-3-Luc cell line were 
injected into the mice via intra-cardiac injection as shown 
in Figure 6A. Subsequent development of metastatic 
tumors was then determined by bioluminescence (Figure 
6B) and ex vivo (Figure 6C and Suppl Figure 3) imaging. 
While mice injected with the Tie-2Low cells failed to 
develop any tumors, metastatic tumors were found in 
3 out of the 8 mice that were injected with the Tie-2High 
population. Of the 3 mice that developed tumors, two 
exhibited bone metastasis and one exhibited soft tissue 
Figure 5: Tie-2 facilitated the adhesion of prostate cancer cells to osteoblasts and endothelial cells. A cell adhesion assay 
was performed with the sorted Tie-2High and Tie-2Low PC-3 cells prestained with Hoechst 33342. Cells that adhered to osteoblasts (MG-63) 
A. or endothelial cells (HUVECs) D. were quantified by measuring the fluorescence intensity, and the results are presented as the mean ± 
SD. Note that Tie-2High PC-3 cells were more adhesive to MG-63 and HUVECs when compared to Tie-2LowPC-3 cells. B&E. Effect of Tie-2 
inactivation on the adhesive ability of Tie-2High PC-3 cells. Treatment with a Tie-2 inhibitor (5 µM) prior to the adhesion assay significantly 
suppressed the adhesion ability of Tie-2High cells, while the same treatment failed to affect the Tie-2Low population. C&F. Ectopic Tie-2 
expression promoted the adhesion of DU145 cells to osteoblast MG-63 cells and HUVECs. Each experiment was repeated at least three 
times, and the results are presented as the mean ± SD. (p values: * < 0.05, ** < 0.005, *** < 0.0005).
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metastasis to the kidney, as shown in Figure 6D. These 
data strongly support that Tie-2High prostate cancer cells are 
highly metastatic and have the ability to form metastatic 
tumors in vivo.
DISCUSSION
In this study, we showed that a rare population of 
Tie-2-positive cells are present in bone metastatic prostate 
cancer cell lines (PC-3, C42b and MDA-PCa-2b). These 
cells not only demonstrated an increased ability to adhere 
to osteoblasts and endothelial cells but were also found 
to be more resistant to chemotherapeutic drugs when 
compared to the Tie-2Low population. More importantly, 
we found that these cells were capable of developing 
into metastatic tumors in vivo, even when a low number 
of cells were injected. These cells may thus represent 
the prostate CSC-like population, which contributes to 
treatment failure and disease metastasis. 
Ample evidence has suggested that CSCs isolated 
from solid tumors share similar characteristics with HSCs 
[26-28]. Indeed, several signalling pathways involved 
in HSC maintenance were also found to be activated in 
CSCs. For example, CXCL12/CXCR4 was found to be 
a key regulator of tumor dissemination in cancer cells 
[29-31], including prostate cancer cells [10, 32] and it 
also plays an important role in the activation of prostate 
progenitor cells [33]. Recently, KITLG/c-Kit was found to 
be involved in CSC maintenance in different cancer types, 
including prostate cancer [34-37]. Moreover, these studies 
also showed that the c-Kit receptor was highly expressed 
in human prostate tumors that metastasized to the bone 
Figure 6: The Tie-2High population was highly metastatic in vivo. A. Tie-2High and Tie-2Low populations sorted out by FACS were 
injected into mice via intracardiac injection (top). An experimental regimen showing the intracardiac implantation and monitoring of tumor 
metastasis is shown below. B. Representative bioluminescence images of a mouse from each group 4 and 8 weeks after the implantation. 
C. Ex vivo imaging of the Tie-2High metastatic tumors. D. Summary of the metastatic tumors detected in each mouse. Three out of the eight 
mice that were injected with Tie-2High cells exhibited metastasis (two in the bone and one in the kidney) (p < 0.05). (See also Suppl Figure 3)
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[38]. It is therefore not surprising that the Ang-1/Tie-2 
signaling pathway may also play a key role in regulating 
the stemness of prostate CSCs, particularly because Tie-2 
was found to be expressed by glioma stem cell populations 
[22]. Indeed, our results suggest that activation of Tie-2 
may be required for maintaining both the stemness and 
quiescent state of prostate cancer cells. The finding that 
the Tie-2High population was more resistant to Cabazitaxel 
further supports this notion. Meanwhile, we also observed 
a significant increase in HSC factors/markers (KITLG, 
CXCR4 and FGF1) in Tie-2High PC-3 cells when compared 
to the Tie-2Low population, further suggesting that Tie-2High 
prostate cancer cells are similar to HSCs.
Prostate cancer cells are known to actively secrete a 
large amount of Ang-1, which induces tumor angiogenesis 
by binding to and activating Tie-2 in endothelial cells [39, 
40]. Our finding that prostate cancer cells also express 
functional Tie-2 suggests that Ang-1 may also function 
through an autocrine loop. Indeed, knockdown of either 
Ang-1 or Tie-2 was found to downregulate CSC and 
quiescence markers in PC-3 and C42B cells. Further 
support was derived from the finding that C42B cells, 
which express the highest level of Ang-1, failed to respond 
to exogenous Ang-1 unless endogenous Ang-1 was 
knocked down by siRNA transfection (data not shown). 
It is worth noting that autocrine loops such as KITLG/c-
Kit and CXCL12/CXCR4 may also exist, although their 
underlying functions and therapeutic potential remain to 
be elucidated. 
Apart from regulating the stemness of HSC, the 
Ang-1/Tie-2 pathway is also known to facilitate the 
adhesion of HSCs to the osteoblastic niche [15]. Similarly, 
in our in vitro adhesion assays, compared to Tie-2Low cells, 
Tie-2High PC-3 cells were more adhesive to osteosarcoma 
MG-63 and SaOS-2 cells. This result suggests that Tie-
2 receptor may also play a key role in mediating the 
adhesion of prostate cancer cells to osteoblasts. This 
possibility was further confirmed by our finding that Tie-
2 overexpression promoted the adhesion of DU145 cells 
to osteoblast cells. Interestingly, similar effects were also 
observed in endothelial cells, where Tie-2High PC-3 cells 
showed increased adhesion to endothelial cells, where 
Tie-2High PC-3 showed increased adhesion to endothelial 
cells. Because both intravasation and extravasation of 
tumor cells required their active adhesion to endothelial 
cells [41, 42], it is conceivable that Tie-2 may play roles in 
both processes during the development of prostate tumor 
metastasis and that Tie-2High prostate cancer cells are 
likely to be more metastatic. This was indeed confirmed 
by the finding that injection of only 3,000 Tie-2High cells 
could induce the formation of metastatic tumors in vivo. 
Interestingly, kidney metastasis was found in one of the 
mice, which may reflect the rich blood supply of the 
kidney tissue. Indeed, sub-renal capsule grafting has been 
shown to provide the optimum microenvironment for 
tumor growth, and was most efficient in terms of uptake 
rate (>90%) for both benign and malignant prostate tissues 
[43].
In summary, we have demonstrated for the first time 
that Tie-2 is expressed by a rare population of prostate 
cancer cells and plays an important role in regulating the 
stemness and metastatic ability of the cells (summarized 
in Suppl Figure 4). Our results highlight the therapeutic 
potential of targeting Tie-2 with existing inhibitors for the 
treatment of metastatic prostate cancer, which warrants 
further investigation.
MATERIALS AND METHODS
qRT-PCR analysis
Total RNA was isolated using an RNeasy Mini 
Kit (Qiagen, Germantown, MD, USA) following the 
manufacturer’s instructions. Two micrograms of RNA 
were used to synthesize cDNA using the SuperScript® III 
First-Strand Synthesis Systems (Invitrogen, Carlsbad, CA, 
USA). qRT-PCR was carried out with the ViiA™ 7 Real-
Time PCR System (Applied Biosystems, Foster City, CA, 
USA). Sense and anti-sense primers targeted against the 
genes of interest are listed in Suppl Table 1. The transcript 
level of ribosomal protein L32 (RPL32) was used as an 
internal control.
Small interfering RNA
Small interfering RNAs (siRNAs) targeting Tie-2 
(J-003178-11 and J-003178-12) and Ang-1 (J-007802-
07 and J-007802-08) as well as a scrambled RNA oligo 
were purchased from Dharmacon, Lafayette, CO, USA. 
Cells were transfected with the indicated siRNA using 
Lipofectamine RNAiMax (Invitrogen) following the 
manufacturer’s instructions. Forty-eight hours after 
transfection, the cells were lysed for Western blotting 
analysis or for RNA extraction and qRT-PCR analysis.
Flow cytometry analysis and fluorescence-
activated cell sorting (FACS)
Cells were collected, washed twice with phosphate-
buffered saline (PBS) and resuspended in 50 µl of FACS 
buffer (0.02% sodium azide and 2% FBS in PBS) before 
incubating with the fluorescent dye-conjugated antibodies 
at 4°C in the dark for 30 minutes. After incubation, the 
cells were washed twice with PBS and subsequently 
resuspended in 200 µl of FACS buffer. Flow cytometry 
analysis was performed using BD™ LSR II as described 
in the manufacturer’s instruction manual, and the results 
were analyzed using KALUZA software.
For cell sorting, PC-3 cells were stained with 
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Phycoerythrin (PE)-conjugated Tie-2 antibody in 200 
µl of FACS buffer (2% FBS in PBS) at 4°C in the dark 
for 2 hours and the corresponding IgG isotype was used 
as negative control. After incubation, cells were washed 
twice with PBS and then resuspended in 500 µl of FACS 
buffer. The Tie-2High population was sorted using the 
Beckman Coulter MoFloAstrio.
Immunohistochemistry (IHC)
Sections rehydrated with standard procedures were 
incubated with 3% hydrogen peroxide (Sigma-Aldrich) 
for 10 minutes at room temperature. Antigen retrieval was 
performed with sodium citrate buffer at pH 6 in a pressure 
cooker for 10 minutes. Sections were then blocked with 
normal goat serum diluted in TBS for 1 hour. After the 
blocking, the sections were incubated with antibody 
against Tie-2 (1: 5000) (Santa Cruz Biotechnology, Dallas, 
TX, USA) for 1 hour, followed by a 1 hour incubation 
with biotinylated rabbit secondary antibody (Vector 
Laboratories, Burlingame, CA, USA) and a 30 minute 
incubation with VECTASTAIN® ABC Reagent complex. 
Signals were developed with the ImmPACT DAB 
Peroxidase (HRP) Substrate (Vector Laboratories). Slides 
were then counterstained with hematoxylin (Biocare 
Medical, Concord, CA, USA) before being mounted for 
analysis under the microscope.
Generation of the stable Tie-2 overexpressing line
DU145 cells overexpressing Tie-2 (DU-Tie-2-GFP) 
were generated using the lentiviral gene delivery system 
as described in our previous study [44]. Briefly, pLenti6-
Tie-2-GFP or the empty vector control was transfected 
into 293FT cells for lentiviral packaging. Viruses were 
collected and used to infect DU145 cells in the presence 
of polybrene (8µg/ml). Positive transfectants were selected 
with blasticidin (10µg/ml) and were further enriched by 
FACS based on the GFP signal.
Western blot
Details regarding the experimental procedures 
have been described in our previous studies [45]. Briefly, 
whole cell lysates were prepared by lysing cell pellets 
with lysis buffer (Cell Signaling) containing 100 µM 
phenylmethylsulfonyl fluoride (PMSF; Sigma-Aldrich, 
St. Louis, MO, USA). The cell lysates were quantitated 
using the Pierce™ BCAProtein Assay Kit (Thermo Fisher 
Scientific, Rockford, IL, USA) before loading onto a 
SDS-polyacrylamide gel. The resolved proteins were then 
transferred onto a PVDF membrane (Millipore, Billerica, 
MA, USA), and the membrane was subsequently probed 
with the indicated antibody for 1 hour at room temperature 
prior to being washed with TBS-T buffer. The membrane 
was then incubated with the corresponding secondary 
antibodies for another hour at room temperature. After 
washing with TBS-T buffer, the membrane was incubated 
with Immobilon Western Chemiluminescent HRP 
Substrate (Millipore), and the signals were visualized 
using a Bio-Rad ChemiDoc™ XRS Gel Documentation 
System.
Hoechst33342/ Pyronin Y (HO/PY) quiescent 
staining 
To determine the percentage of quiescent cells, all 
cells were first stained with 10 µg/ml HO for 45 minutes in 
the dark at 37°C. The cells were then incubated with 5 µM 
PY for another 45 minutes in the dark at 37°C as described 
in previous studies [46-48]. After staining, the cells were 
analyzed using BD™ LSR II, and the results were further 
analyzed using KALUZA software.
Annexin V staining
To determine the percentage of apoptotic 
cells, Annexin V staining was performed using BD 
Pharmingen™ Annexin V-FITC kits following the 
manufacturer’s instructions. Briefly, Tie-2High and Tie-2Low 
PC-3 cells were washed twice with cold PBS, resuspended 
in 100µl of 1X binding buffer and then incubated with 
Annexin V-FITC antibody and propidium iodide in the 
dark at room temperature for 15 minutes. After incubation, 
the apoptotic cells were analyzed using BD™ LSR II, 
and the results were further analyzed using KALUZA 
software.
Ang-1 ELISA
To quantitate Ang-1 secretion by the prostate cancer 
cells, the cells were cultured in serum-free medium 
for 24 hours. The cells were harvested and counted 
using a Scepter™ Automated Cell Counter (Millipore). 
Conditioned medium was collected and concentrated 
using the 10K Amicon Ultra2-ml Centrifugal Filters 
(Millipore). The medium was analyzed using the Human 
Angiopoietin-1 DuoSet kits (R&D Systems, Minneapolis, 
MN, USA) following the manufacturer’s instructions and 
the positive signals were determined using a LUMIstar 
OPTIMA Luminescence Microplate Reader and then, 
normalized it to the cell numbers.
Cell adhesion assay
Prostate cancer cell lines were first labelled with 
HO for 45 minutes. Labelled cells (3 X 103) were then 
overlaid directly onto confluent HUVECs, MG-63 cells 
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or SaOS-2 cells. The cells were incubated for 30 minutes 
in the dark at 37°C. Unattached cells were dispersed 
with PBS, and the adherent cells were quantified using 
a LUMIstar OPTIMA Luminescence Microplate Reader. 
This experiment was repeated in the presence of 5 µM 
Tie-2 inhibitor or an equal volume of DMSO as a control. 
The data are presented as the fluorescence intensity from 
triplicate experiments.
Animal studies
All animal studies were conducted in accordance 
with the Australian Code of Practice for the Care and Use 
of Animals for Scientific Purposes and were approved 
by the Animal Ethics Committee at the Queensland 
University of Technology (Approval No: 1100001393). 
Tumor metastasis were examined via intra-cardiac tumor 
cell injection using procedures described previously [23]. 
Briefly, the Tie-2High population was isolated from PC3-
Luc cells, which were stably transfected with a luciferase 
expression construct [44]. Three thousand Tie-2High or 
Tie-2Low cells were suspended in 100 µl of PBS before 
injecting into the left cardiac ventricle of 6-8-week-
old male NOD-SCID mice (n = 8). Tumor metastasis 
were monitored every 2 weeks for a total of 8 weeks 
by intraperitoneal injection of D-luciferin (150 mg/kg) 
followed by bioluminescence imaging. The signal was 
detected using the Xenogen IVIS 100 imaging system. 
Mice were sacrificed at the end of the experiment, and ex 
vivo bioluminescence imaging was performed to confirm 
the incidence of metastasis. Statistical analysis was 
performed with the two-tailed t test, and differences were 
considered to be significant if p < 0.05.
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